Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study.
Kizilors A, Crisà E, Lea N, Passera R, Mian S, Anwar J, Best S, Nicolini FE, Ireland R, Aldouri M, Pocock C, Corbett T, Gale R, Bart-Smith E, Weston-Smith S, Wykes C, Kulasekararaj A, Jackson S, Harrington P, McLornan D, Raj K, Pagliuca A, Mufti GJ, de Lavallade H. Kizilors A, et al. Among authors: de lavallade h. Lancet Haematol. 2019 May;6(5):e276-e284. doi: 10.1016/S2352-3026(19)30027-4. Lancet Haematol. 2019. PMID: 31036317
In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib.
Khorashad JS, Milojkovic D, Mehta P, Anand M, Ghorashian S, Reid AG, De Melo V, Babb A, de Lavallade H, Olavarria E, Marin D, Goldman JM, Apperley JF, Kaeda JS. Khorashad JS, et al. Among authors: de melo v, de lavallade h. Blood. 2008 Feb 15;111(4):2378-81. doi: 10.1182/blood-2007-06-096396. Epub 2007 Nov 2. Blood. 2008. PMID: 17982022 Free article. Clinical Trial.
Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression.
Khorashad JS, de Lavallade H, Apperley JF, Milojkovic D, Reid AG, Bua M, Szydlo R, Olavarria E, Kaeda J, Goldman JM, Marin D. Khorashad JS, et al. Among authors: de lavallade h. J Clin Oncol. 2008 Oct 10;26(29):4806-13. doi: 10.1200/JCO.2008.16.9953. Epub 2008 Jul 21. J Clin Oncol. 2008. PMID: 18645191 Free PMC article.
Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
Milojkovic D, Nicholson E, Apperley JF, Holyoake TL, Shepherd P, Drummond MW, Szydlo R, Bua M, Foroni L, Reid A, Khorashad JS, de Lavallade H, Rezvani K, Paliompeis C, Goldman JM, Marin D. Milojkovic D, et al. Among authors: de lavallade h. Haematologica. 2010 Feb;95(2):224-31. doi: 10.3324/haematol.2009.012781. Epub 2009 Oct 14. Haematologica. 2010. PMID: 19833633 Free PMC article.
Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy.
Ibrahim AR, Paliompeis C, Bua M, Milojkovic D, Szydlo R, Khorashad JS, Foroni L, Reid A, de Lavallade H, Rezvani K, Dazzi F, Apperley JF, Goldman JM, Marin D. Ibrahim AR, et al. Among authors: de lavallade h. Blood. 2010 Dec 16;116(25):5497-500. doi: 10.1182/blood-2010-06-291922. Epub 2010 Sep 10. Blood. 2010. PMID: 20833982 Free PMC article. Clinical Trial.
KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib.
Marin D, Gabriel IH, Ahmad S, Foroni L, de Lavallade H, Clark R, O'Brien S, Sergeant R, Hedgley C, Milojkovic D, Khorashad JS, Bua M, Alsuliman A, Khoder A, Stringaris K, Cooper N, Davis J, Goldman JM, Apperley JF, Rezvani K. Marin D, et al. Among authors: de lavallade h. Leukemia. 2012 Feb;26(2):296-302. doi: 10.1038/leu.2011.180. Epub 2011 Aug 16. Leukemia. 2012. PMID: 21844874
Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes.
Krishnamurthy P, Potter VT, Barber LD, Kulasekararaj AG, Lim ZY, Pearce RM, de Lavallade H, Kenyon M, Ireland RM, Marsh JC, Devereux S, Pagliuca A, Mufti GJ. Krishnamurthy P, et al. Among authors: de lavallade h. Biol Blood Marrow Transplant. 2013 Apr;19(4):562-8. doi: 10.1016/j.bbmt.2012.12.013. Epub 2012 Dec 21. Biol Blood Marrow Transplant. 2013. PMID: 23266740 Free article.
Long-term outcomes of alemtuzumab-based reduced-intensity conditioned hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia secondary to myelodysplastic syndrome.
Potter VT, Krishnamurthy P, Barber LD, Lim Z, Kenyon M, Ireland RM, de Lavallade H, Dhouri A, Marsh JC, Marcus R, Devereux S, Ho A, Pagliuca A, Mufti GJ. Potter VT, et al. Among authors: de lavallade h. Biol Blood Marrow Transplant. 2014 Jan;20(1):111-7. doi: 10.1016/j.bbmt.2013.10.021. Epub 2013 Nov 8. Biol Blood Marrow Transplant. 2014. PMID: 24216184 Free article.
Autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: analysis of 533 adult patients who underwent transplantation at King's College Hospital.
Wang M, Wang W, Abeywardane A, Adikarama M, McLornan D, Raj K, de Lavallade H, Devereux S, Mufti GJ, Pagliuca A, Potter VT, Mijovic A. Wang M, et al. Among authors: de lavallade h. Biol Blood Marrow Transplant. 2015 Jan;21(1):60-6. doi: 10.1016/j.bbmt.2014.09.009. Epub 2014 Sep 28. Biol Blood Marrow Transplant. 2015. PMID: 25262883 Free article.
82 results